

**BEST AVAILABLE COPY**

Sheet 1 of 1

Form PTO-1449 (Rev. 3-03)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number		Application Number	
				00509/2/US		10/414,852	
				First Named Inventor			
				Kevin E. Henegar			
				Filing Date	Group Art Unit		
				April 18, 2003	Unknown		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date If Appropriate
<i>H</i>		US 6,121,451	Sep 19, 2000	Henegar et al.	546	92	
Examiner <i>Raymond Conner</i>		Date Considered <i>11/28/03</i>					
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**BEST AVAILABLE COPY**



## BEST AVAILABLE COPY

Sheet 1 of 1

Form PTO-949 (Rev. 1-2000)	U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			00509/2/US	10/414,852
			Applicant	
			Henegar, K.E.	
			Filing Date	Group No.
			April 16, 2003	1614
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)				
X		Josien et al. (1998) A general synthetic approach to the (20S)-camptothecin family of antitumor agents by a regiocontrolled cascade radical cyclization of aryl isonitriles. Chemistry – A European Journal 4(1), 67–83.		
Examiner	Date Considered			
<i>Raymond Gaylor</i>	11/20/03			
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				